Cancer drug duo trial halted after just one patient
Disease control
Terminated
This study aimed to test whether adding the drug regorafenib to the approved immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced colorectal cancer that has specific genetic features (called MSI-H). The trial was designed to first check safet…
Phase: PHASE2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC